"Radioimmunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
| Descriptor ID |
D016499
|
| MeSH Number(s) |
E02.095.465.425.750 E02.186.750 E02.815.520
|
| Concept/Terms |
Radioimmunotherapy- Radioimmunotherapy
- Radioimmunotherapies
- Immunoradiotherapy
- Immunoradiotherapies
|
Below are MeSH descriptors whose meaning is more general than "Radioimmunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Radioimmunotherapy".
This graph shows the total number of publications written about "Radioimmunotherapy" by people in this website by year, and whether "Radioimmunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 0 | 3 |
| 1997 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 5 | 6 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radioimmunotherapy" by people in Profiles.
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
-
Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon? Cancer Cell. 2024 01 08; 42(1):10-12.
-
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
-
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
-
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
-
A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnology. 2021 Dec 11; 19(1):416.
-
Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer. 2021 10; 45(5):100796.
-
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst. 2021 10 01; 113(10):1396-1404.
-
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. Front Immunol. 2021; 12:625783.
-
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67.